Patients with BRAF wild-type tumours, absence of brain and/or liver metastases, and a low tumour burden are particularly suitable candidates for anti-PD-1 monotherapy [2–4] In BRAF-mutant patients, the combination of BRAF and MEK inhibitors, following the findings of DREAMseq trial, has become a less prioritised treatment option. This evidence concerns the gene BRAF and neoplasm.